<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lian X</submitter><funding>National Natural Science Foundation of China</funding><funding>Climbing Project for Medical Talent of Zhongnan Hospital of Wuhan University</funding><funding>Noncommunicable Chronic Diseases-National Science and Technology</funding><pagination>bbaf266</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12145228</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(3)</volume><pubmed_abstract>Depicting a global landscape of essential gene-targeting drugs would provide more opportunities for cancer therapy. However, a systematic investigation on drugs targeting essential genes still has not been reported. We suppose that drugs targeting cancer-type-specific essential genes would generally have less toxicity than those targeting pan-cancer essential genes. A scoring function-based strategy was developed to identify cancer-type-specific targets and drugs. The EssentialitySpecificityScore ranked the essential genes in 19 cancer types, and 1151 top genes were identified as cancer-type-specific targets. Combining target-drug interaction databases with research/marketing status, 370 cancer-type-specific drugs were identified, bound to 100 out of all identified targets. Profiles of app</pubmed_abstract><journal>Briefings in bioinformatics</journal><pubmed_title>Systematic identification of cancer-type-specific drugs based on essential genes and validations in lung adenocarcinoma.</pubmed_title><pmcid>PMC12145228</pmcid><funding_grant_id>2023ZD0506200</funding_grant_id><funding_grant_id>32370696</funding_grant_id><funding_grant_id>PDJH202406 and PDJH202205</funding_grant_id><pubmed_authors>Cui HT</pubmed_authors><pubmed_authors>Zhang DD</pubmed_authors><pubmed_authors>Ye A</pubmed_authors><pubmed_authors>Guo HX</pubmed_authors><pubmed_authors>Lian X</pubmed_authors><pubmed_authors>Xu Q</pubmed_authors><pubmed_authors>Kuang X</pubmed_authors><pubmed_authors>Hao GF</pubmed_authors><pubmed_authors>Cheng Z</pubmed_authors><pubmed_authors>Guo FB</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Wang CY</pubmed_authors><pubmed_authors>Zhang JY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Systematic identification of cancer-type-specific drugs based on essential genes and validations in lung adenocarcinoma.</name><description>Depicting a global landscape of essential gene-targeting drugs would provide more opportunities for cancer therapy. However, a systematic investigation on drugs targeting essential genes still has not been reported. We suppose that drugs targeting cancer-type-specific essential genes would generally have less toxicity than those targeting pan-cancer essential genes. A scoring function-based strategy was developed to identify cancer-type-specific targets and drugs. The EssentialitySpecificityScore ranked the essential genes in 19 cancer types, and 1151 top genes were identified as cancer-type-specific targets. Combining target-drug interaction databases with research/marketing status, 370 cancer-type-specific drugs were identified, bound to 100 out of all identified targets. Profiles of app</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-06-02T22:25:45.809Z</modification><creation>2026-04-21T03:13:35.777Z</creation></dates><accession>S-EPMC12145228</accession><cross_references><pubmed>40483547</pubmed><doi>10.1093/bib/bbaf266</doi></cross_references></HashMap>